BAX stock sentiment todayBaxter International Inc.
Sentiment verdict
Gossip first, financials second — COLD at 85% confidence.
Last updated · cached analysis, refreshes periodically
BAX
Baxter International Inc.A struggling legacy medtech giant facing heavy debt, operational headwinds, and a massive spin-off execution risk.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for BAX. Not financial advice.
Price · last 12 months
Gossip
The market is losing patience with Baxter's prolonged turnaround and the delayed spin-off of its Vantive (Kidney Care) segment. Investor sentiment is weighed down by the recent SEC investigation into accounting errors and the massive debt load following the Hillrom acquisition.
- ·Vantive spin-off delays and execution risk
- ·Supply chain disruptions in IV solutions (Hurricane Helene impacts)
- ·Lack of confidence in management's ability to de-lever
Financial
Baxter is fundamentally challenged by a high debt-to-EBITDA ratio and thinning margins. While the company generates consistent cash flow, it is heavily diverted to interest payments rather than R&D or growth.
- ·P/E Ratio (Forward): ~8.5x (indicates value trap territory)
- ·Net Debt: ~$11B (high leverage relative to market cap)
- ·Operating Margin: Under pressure due to inflationary costs in medical supplies
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High interest rate sensitivity due to floating debt exposure
- ·Competitive erosion in the medication delivery market
- ·Potential for further asset impairment charges
Peer temperature
How direct competitors stack up against BAX right now.
- HOTBDXBecton, Dickinson and Company
HOTTER — significantly more stable revenue streams and a superior track record of dividend growth.
See full analysis → - NEUTRALMDTMedtronic plc
WARMER — trading at a higher valuation but offers a much more diversified product portfolio and better R&D pipeline.
See full analysis → - NEUTRALICUICU Medical, Inc.
NEUTRAL — faces similar supply chain issues but has a cleaner balance sheet without the massive debt overhang of a major acquisition.
See full analysis →
- BAX-8.6%
- BDX-5.7%
- MDT-6.3%
- ICU+62.8%
Analyst price target
Consensus average of 11 analysts · median 27.00
Source: StockAnalysis.com · updated 2026-08-13
AI-generated analysis for informational purposes only. Not financial advice.